Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF status.

Authors:
Dominick Leone, MPH, MS
Dominick Leone, MPH, MS
Boston University School of Public Health
Pre-Doctoral Candidate
Precision Approach to Population Health: Genomic and Infectious Disease Epidemiology
Boston, Massachusetts | United States

Hum Pathol 2015 Feb 26;46(2):304-12. Epub 2014 Nov 26.

Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA 02118. Electronic address:

The relationship between microvessel density (MVD), lymphovascular density (LVD), and lymphovascular invasion (LVI) in primary cutaneous melanoma (PCM) remains unclear. Given this, a total of 102 PCMs were assessed for MVD (vascular endothelial growth factor receptor 2 and Endocan), LVD (D2-40), and LVI (immunostaining with D2-40/S-100 and hematoxylin and eosin); tumoral S-100A13, vascular endothelial growth factor receptor 2, and Endocan; and BRAF status. LVD was associated with MVD (P = .01). MVD was higher in PCMs with depth greater than or equal to 2 mm and ulceration (P = .04, .05), whereas LVD was higher in PCMs with depth greater than or equal to 2 mm and mitoses (P = .03, .02). After adjusting for MVD and LVD, only ulceration was associated with LVI (P < .02). A BRAF mutation was seen in 30.4% cases, and when present, both LVD and host response (P = .0008 and .04, respectively) were significantly associated with MVD. Immunostaining with S-100A13 was noted in 99% of cases and a significant association noted only with ulceration (P = .05). Immunostaining increased LVI positivity (46.5% versus 4.9% by hematoxylin and eosin, P < .0001). MVD and LVD are not associated with LVI, appear to be closely related with each other, and are associated with select markers of poor prognosticative value. The association between a host response and LVD and MVD in PCMs with a BRAF mutation suggests that they exhibit potential for strategizing immunotherapies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2014.11.006DOI Listing
February 2015
19 Reads
2 Citations
2.770 Impact Factor

Publication Analysis

Top Keywords

factor receptor
8
mvd lvd
8
mvd
8
receptor endocan
8
depth greater
8
greater equal
8
lvd
8
growth factor
8
braf mutation
8
host response
8
associated lvi
8
vascular endothelial
8
endothelial growth
8
pcms depth
8
braf status
8
lymphovascular invasion
8
lvd associated
8
primary cutaneous
8
higher pcms
8
associated mvd
8

Similar Publications